Increasing studies have shown that FOXM1 is extensively overexpressed in most human malignancies, including HCC, breast cancer and lung cancer, and its increased expression may serve as a biomarker and indicate the poor outcome of patients16–19. This evidence concerns the gene FOXM1 and hepatocellular carcinoma.